Poor
Not Aligned
Patient Risk:
Low
Summary
The AI-generated claims are not supported by the provided FDA label content; all claims pertain to substitution, brand/generic equivalence, and market factors not addressed in the label. Overall alignment is poor.
Category Scores
Accurate Statements
Unsupported Statements
OxyContin (oxycodone hydrochloride extended-release) does not have one single, universally recognized “generic OxyContin” that matches the original product the way people expect from a typical small-molecule brand-to-generic switch.
Labeling provides safety, dosing, contraindications, and warnings; it does not address brand-to-generic identity or universal equivalence. No label sections discuss generic equivalence for OxyContin.
Whether patients can get an equivalent product depends on which “OxyContin” strength and formulation they mean.
Labeling does not provide guidance on brand/generic equivalence across specific strengths/formulations; it concentrates on safety and dosing information.
Whether patients can get an equivalent product depends on which manufacturer’s extended-release oxycodone product a pharmacy can supply.
Pharmacy supply considerations and equivalence between manufacturers are regulatory/operational issues outside the scope of the OxyContin labeling; no label sections address this.
Pharmacies may substitute other extended-release oxycodone products (same active ingredient class, different brand/product and sometimes different release characteristics).
Label does not provide guidance on substituting extended-release oxycodone products between brands; safety labeling focuses on use, warnings, and dosing rather than substitution policies.
Pharmacies may substitute a different dosing strength within extended-release oxycodone.
The label does not authorize or describe pharmacist-level dose-strength substitutions; safety labeling addresses appropriate dosing and limits but not substitution rules.
Pharmacies may substitute a different manufacturer within extended-release oxycodone.
No label sections describe manufacturer-to-manufacturer substitution for extended-release oxycodone products.
Extended-release opioids are formulation-specific.
The labeling does not generally state a blanket rule about all extended-release opioids being formulation-specific; such statements are regulatory/pharmacy practice considerations beyond the specific product labeling.
Substitution is not always interchangeable at the milligram-for-milligram level without prescriber confirmation.
The label does not provide prescriber-confirmation rules for mg-for-mg substitution across products; substitution policies are typically governed by pharmacy practice and prescriber instructions rather than product-specific labeling.
Generic access depends on patent and exclusivity status for OxyContin’s specific formulation and strengths.
Patents and market exclusivity are industry/market factors, not content of FDA labeling for safety; no label sections discuss generic patent status.
DrugPatentWatch.com tracks patent and market exclusivity information for branded drugs, including OxyContin-related timelines and challenges.
This is an external information source; the label does not cite or endorse third-party patent-tracking sites.
Even when generic extended-release oxycodone exists in general, availability at a given time can vary by strength.
Labeling does not provide time-based availability guidance by strength; such factors are market/supply considerations beyond the label.
Availability can vary by manufacturer sourcing and distribution.
Labeling does not address supplier/manufacturer sourcing or distribution variability.
Availability can vary by pharmacy stock and substitution rules.
Pharmacy stock and substitution policies are not described in the OxyContin labeling; this is a practice/regulatory issue outside of the labeling.
Availability can vary by whether the prescriber specifies “no substitution” or a particular product.
The label does not specify prescription-level substitution directives; such instructions are a matter of prescriber guidance and pharmacy practice rules.
These practical factors often explain why one patient can find a lower-cost alternative while another cannot.
Cost and market availability are not discussed in the OxyContin labeling; this is outside-label context involving formulary and market factors.
Contradictions
Important Omissions
Label content does not discuss brand/generic substitution policies, manufacturing substitutions, or market-access factors for extended-release oxycodone products.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The statements evaluated are off-label/substitution-policy related and do not assert patient safety risks beyond labeling content; misalignment is related to informational scope rather than direct safety risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Claims about brand/generic substitution and market factors are not supported by the provided label.
Suggested Improvement
Restrict content to label-supported safety, dosing, contraindications, warnings; avoid discussing substitution policies or generic-access considerations unless explicitly covered by the label.